The latest price target for Globus Medical (NYSE:GMED) was reported by Morgan Stanley on November 11, 2024. The analyst firm set a price target for $83.00 expecting GMED to fall to within 12 months (a possible -1.47% downside). 34 analyst firms have reported ratings in the last year.

The latest analyst rating for Globus Medical (NYSE:GMED) was provided by Morgan Stanley, and Globus Medical maintained their equal-weight rating.

The last upgrade for Globus Medical Inc happened on August 7, 2024 when Wells Fargo raised their price target to $78. Wells Fargo previously had an equal-weight for Globus Medical Inc.

The last downgrade for Globus Medical Inc happened on February 13, 2023 when B of A Securities changed their price target from $83 to $63 for Globus Medical Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Globus Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Globus Medical was filed on November 11, 2024 so you should expect the next rating to be made available sometime around November 11, 2025.

While ratings are subjective and will change, the latest Globus Medical (GMED) rating was a maintained with a price target of $74.00 to $83.00. The current price Globus Medical (GMED) is trading at is $84.24, which is out of the analyst’s predicted range.